Orthofix Medical Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
On May 29, 2026, Patrick Fisher, President, Global Biologics and Limb Reconstruction, adopted a Rule 10b5-1 Trading Plan. Mr. Fisher’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of August 31, 2027, or the sale of all shares subject to the plan, provides for the sale of up to 1,800 shares of common stock pursuant to the terms of the plan. Mr. Fisher’s 10b5-1 Trading Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Other than as discussed above, during the last fiscal quarter, none of our other directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted, modified orterminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any "non-Rule 10b5-1 trading arrangement."
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.